Compare Centene Corp (CNC) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centene Corp vs 22nd Century Group Inc — how do they compare? Centene Corp trades at $67.39 (market cap $32.05B), while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: Centene Corp is far larger — about 21085.5× 22nd Century Group Inc's market cap, and Centene Corp is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| CNC | XXII | |
|---|---|---|
Market Cap | $32.05B | $1.52M |
Sector | Health | Technology |
52-Week High | $68.72 | $801.00 |
52-Week Low | $26.17 | $3.72 |
Enterprise Value | $21.10B | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centene (CNC) trades at $67.35, up 1.19% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock has beaten earnings estimates in recent quarters, including Q2 2026 EPS of $2.51 versus $1.09 expected, and shows robust cash flow trends with 2025 net cash flow of $3.94 billion. Recent news highlights margin recovery and raised 2026 guidance, reinforcing positive momentum.
The outlook remains favorable given valuation discounts (P/E of 8.06, P/S of 0.16) and analyst consensus price target of $71.00, though risks include negative net income margins and Medicaid membership volatility. Upside potential hinges on execution of cost controls and premium growth in government-sponsored health plans.
XXII trades at $4.38, up 0.69% with neutral technical signals. The company shows concerning fundamentals with negative profit margins (-65.76% net income margin) and ROE of -130.19%, though valuation ratios appear low (P/S 0.03, P/B 0.07). Recent corporate actions include a 20:1 reverse stock split in June 2026. Analyst sentiment remains positive with 75% buy ratings, while the company expands VLN® product distribution in key markets like California and New York.
The outlook remains speculative given persistent losses despite revenue generation. Investment opportunity lies in successful execution of reduced-nicotine cigarette expansion and FDA regulatory progress. Key risks include continued cash burn, competitive pressures, and dependency on regulatory approvals for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
